T-cell vaccine for the treatment of multiple sclerosis (MS
Tovaxin®, a cellular immunotherapy has completed a Phase 2b clinical study for the treatment of multiple sclerosis (MS). Tovaxin is specifically tailored to each patient's disease profile and is designed to reduce the number of specific subsets of autoreactive T-cells known to attack myelin. Treatment will consist of donating blood and creating a vaccine using the patient’s own cells. The vaccine cells will be irradiated to render them unable to divide, but able to evoke an immune response.
Tovaxin is manufactured using Opexa Therapeutics’ proprietary method for the production of patient-specific T-cell vaccines, which comprises the collection of blood from the MS patient, the harvest and expansion of disease-causing T-cells from the blood, and the return of these expanded, irradiated T-cells back to the patient. These attenuated T-cells, which comprise the Tovaxin vaccine, are reintroduced into the patient via subcutaneous injection to trigger a therapeutic immune system response.
The vaccines will be administered in the doctor’s office as a subcutaneous injection in the arm given five times a year. The first four injections are administered a month apart with the fifth and final injection being administered two months after the fourth. For more information on Opexa and Tovaxin, please visit Opexa Therapeutics .
Tovaxin is manufactured using Opexa Therapeutics’ proprietary method for the production of patient-specific T-cell vaccines, which comprises the collection of blood from the MS patient, the harvest and expansion of disease-causing T-cells from the blood, and the return of these expanded, irradiated T-cells back to the patient. These attenuated T-cells, which comprise the Tovaxin vaccine, are reintroduced into the patient via subcutaneous injection to trigger a therapeutic immune system response.
The vaccines will be administered in the doctor’s office as a subcutaneous injection in the arm given five times a year. The first four injections are administered a month apart with the fifth and final injection being administered two months after the fourth. For more information on Opexa and Tovaxin, please visit Opexa Therapeutics .
Posted by Gary at 1/24/2012 9:59 AM 
Categories: New MS Drug, MS community Questions and Answers, About MS, Multiple Scleroses Research
Tags: Multiple sclerosis Reasearch News ms drugs Multiple Scleroses
Categories: New MS Drug, MS community Questions and Answers, About MS, Multiple Scleroses Research
Tags: Multiple sclerosis Reasearch News ms drugs Multiple Scleroses
Hope this works!
Reply to this
Hi Rodney,
So far from what I have seen it works well with certain people. If your T- Cells react to(against) myelin in a test sample then there is a good chance the vaccine will work to prevent actual myelin destruction in the future.
Reply to this
I've checked out all the videos. Sounds very promising. I sent them an email on their site to sign me up. I'm
ready!
Reply to this
I just found your blog and I am very curious as to this whole t-cell/ms/your health as of now...
Did you start this and how are you either way?
I wish u well
Reply to this
Hi Janis,
I am glad you found us.
About Me:
I was diagnosed with MS in 2005, When I was diagnosed I was in PA school and had to withdraw due to side effects from the medication I was taking. It was a very challenging experience for me. From this experience I realized the emotional stress and possible psychological trauma associated with receiving this kind of diagnosis. I decided to use this experience to produce something positive. I helped start Disability Connections in 2009. Our goal is to reach out to others with MS and other chronic conditions. I am thankful that my health is stable, and plan on building this organization in the future. We hope to create a major outreach program that assist people with physical and mental challenges associated with disabilities. I envision our outreach program to become a major asset to people with disabilities. Our goal to provide assistance with mental health counseling, educational scholarships, and financial assistance for medication and mobility equipment.
About the drug :
Tovaxin is an autologous T-cell vaccine, which means it is prepared from a sample of the patient's own cells. Myelin-reactive T-cells are extracted from the blood and irradiated to produce a vaccine. When the vaccine is injected, the body sees these modified T-cells as being foreign and attacks them, priming the immune system to attack non-irradiated, myelin-reactive T-cells as well. Another words your immune system is set to react against the T- cells that are destroying myelin.
The catch here is that not everybody can use it; a person must have active Myelin-reactive T-cells that they can use to form a vaccine. I tried tovolunteer for this study but my T- cells were’t reacting against my Myelin so the vaccine was not able to be formed.
Reply to this